1,349 research outputs found
Study of the vegetation series of Cuenca de Pamplona-Valdizarbe (Navarre-NE Spain): interest of their mapping and application
Se estudian las series y subseries de vegetación de 77.817 ha del centro de Navarra, para su cartografía a escala 1:25.000. Las series y subseries son indicadoras de las características ecológicas del territorio y complementan la información climática disponible. Se han descrito ocho series de vegetación, dos geoseries y dos complejos de vegetación. Las series climatófilas comprenden 28 faciaciones, reconocidas mediante las comunidades vegetales que las integran. La distinción de las faciaciones no sólo está asociada a factores climáticos, sino también a factores geomorfológicos, litológicos, edáficos e históricos. Estos últimos factores permiten reconocer patrones complejos a escalas de detalle, superpuestos a los que reflejan los factores climáticos, evidentes a escalas más reducidas. El estudio se enmarca en un proyecto que pretende definir la potencialidad del territorio para diferentes usos y elaborar modelos de evaluación de tierras en Navarra utilizando las unidades cartográficas reconocidas.The vegetation series and subseries of 77,817 ha of Central Navarre are studied to be used as mapping units of a vegetation series map at scale 1:25,000. The series and subseries are indicators of the land environmental features and may be useful to complete the available climatic data. Eight vegetation series, two geoseries and two vegetation complexes have been described. Climatophilous series include 28 subseries defined by the different plant communities that form each one. While vegetation series show clearly climatic patterns when studied at small scales, at detailed scales the vegetation patterns show also the effects of landforms, lithology, soils and history. This study is part of a project that is intended to assess land suitability for different uses and to work out land evaluation models in Navarre based upon the recognized mapping units
Hospital volume and outcomes for acute pulmonary embolism: Multinational population based cohort study
[Objectives] To evaluate the association between experience in the management of acute pulmonary embolism, reflected by hospital case volume, and mortality.[Design] Multinational population based cohort study using data from the Registro Informatizado de la Enfermedad TromboEmbólica (RIETE) registry between 1 January 2001 and 31 August 2018.[Setting] 353 hospitals in 16 countries.[Participants] 39 257 consecutive patients with confirmed diagnosis of acute symptomatic pulmonary embolism.[Main] outcome measure Pulmonary embolism related mortality within 30 days after diagnosis of the condition.[Results] Patients with acute symptomatic pulmonary embolism admitted to high volume hospitals (>40 pulmonary embolisms per year) had a higher burden of comorbidities. A significant inverse association was seen between annual hospital volume and pulmonary embolism related mortality. Admission to hospitals in the highest quarter (that is, >40 pulmonary embolisms per year) was associated with a 44% reduction in the adjusted odds of pulmonary embolism related mortality at 30 days compared with admission to hospitals in the lowest quarter (<15 pulmonary embolisms per year; adjusted risk 1.3% v 2.3%; adjusted odds ratio 0.56 (95% confidence interval 0.33 to 0.95); P=0.03). Results were consistent in all sensitivity analyses. All cause mortality at 30 days was not significantly reduced between the two quarters (adjusted odds ratio 0.78 (0.50 to 1.22); P=0.28). Survivors showed little change in the odds of recurrent venous thromboembolism (odds ratio 0.76 (0.49 to 1.19)) or major bleeding (1.07 (0.77 to 1.47)) between the low and high volume hospitals.[Conclusions] In patients with acute symptomatic pulmonary embolism, admission to high volume hospitals was associated with significant reductions in adjusted pulmonary embolism related mortality at 30 days. These findings could have implications for management strategies.Peer reviewe
Addressing influenza’s underestimated burden – Iberian experts call to action
Hospitalization; Influenza; PreventionHospitalització; Grip; PrevencióHospitalización; Gripe; PrevenciónHaving a proper understanding of the impact of influenza is a fundamental step towards improved preventive action. This paper reviews findings from the Burden of Acute Respiratory Infections study on the burden of influenza in Iberia, and its potential underestimation, and proposes specific measures to lessen influenza’s impact.The BARI study was funded by Sanofi
Surgery guided by 5-aminolevulinic fluorescence in glioblastoma: volumetric analysis of extent of resection in singlecenter experience
We analyzed the efficacy and applicability of surgery guided by 5-aminolevulinic
acid (ALA) fluorescence in consecutive patients with glioblastoma multiforme
(GBM). Thirty-six patients with GBM were operated on using ALA fluorescence.
Resections were performed using the fluorescent light to assess the right plane
of dissection. In each case, biopsies with different fluorescent quality were
taken from the tumor center, from the edges, and from the surrounding tissue.
These samples were analyzed separately with hematoxylin-eosin examination and
immunostaining against Ki67. Tumor volume was quantified with pre- and
postoperative volumetric magnetic resonance imaging. Strong fluorescence
identified solid tumor with 100% positive predictive value. Invaded tissue beyond
the solid tumor mass was identified by vague fluorescence with 97% positive
predictive value and 66% negative predictive value, measured against
hematoxylin-eosin examination. All the contrast-enhancing volume was resected in
83.3% of the patients, all patients had resection over 98% of the volume and mean
volume resected was 99.8%. One month after surgery there was no mortality, and
new or increased neurological morbidity was 8.2%. The fluorescence induced by
5-aminolevulinic can help to achieve near total resection of enhancing tumor
volume in most surgical cases of GBM. It is possible during surgery to obtain
separate samples of the infiltrating cells from the tumor borde
WITHDRAWN: La enfermedad pulmonar obstructiva crónica como factor de riesgo cardiovascular
This article has been withdrawn at the request of the author(s) and editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy
Hypofractionated radiation therapy and temozolomide in patients with glioblastoma and poor prognostic factors. A prospective, single-institution experience
Background: Hypofractionated radiation therapy is a feasible and safe treatment option in elderly and frail patients with glioblastoma. The aim of this study was to evaluate the effectiveness of hypofractionated radiation therapy with concurrent temozolomide in terms of feasibility and disease control in primary glioblastoma patients with poor prognostic factors other than advanced age, such as post-surgical neurological complications, high tumor burden, unresectable or multifocal lesions, and potential low treatment compliance due to social factors or rapidly progressive disease.
Material and methods: GTV included the surgical cavity plus disease visible in T1WI-MRI, FLAIR-MRI and in the MET-uptake. The CTV was defined as the GTV plus 1.5-2 cm margin; the PTV was the CTV+0.3 cm margin. Forty, fourty-five, and fifty grays in 15 fractions were prescribed to 95% of PTV, CTV, and GTV, respectively. Treatment was delivered using IMRT or the VMAT technique. Simultaneously, 75 mg/m2/day of temozolomide were administered.
Results: Between January 2010 and November 2017, we treated a total of 17 patients. The median age at diagnosis was 68-years; median KPS was 50-70%. MGMT-methylation status was negative in 5 patients, and 8 patients were IDH-wildtype. Eight of 18 patients were younger than 65-years. Median tumor volume was 26.95cc; median PTV volume was 322cc. Four lesions were unresectable; 6 patients underwent complete surgical resection. Median residual volume was 1.14cc. Progression-free survival was 60% at 6 months, 33% at 1-year and 13% at 2-years (median OS = 7 months). No acute grade 3-5 toxicities were documented. Symptomatic grade 3 radiation necrosis was observed in one patient.
Conclusions: Patients with poor clinical factors other than advanced age can be selected for hypofractionated radiotherapy. The OS and PFS rates obtained in our series are similar to those in patients treated with standard fractionation, assuring good treatment adherence, low rates of toxicity and probable improved cost-effectiveness
Burden and challenges of heart failure in patients with chronic kidney disease. A call to action
Patients with the dual burden of chronic kidney disease (CKD) and chronic congestive heart
failure (HF) experience unacceptably high rates of symptom load, hospitalization, and mortality. Currently, concerted efforts to identify, prevent and treat HF in CKD patients are
lacking at the institutional level, with emphasis still being placed on individual specialty
views on this topic. The authors of this review paper endorse the need for a dedicated
cardiorenal interdisciplinary team that includes nephrologists and renal nurses and jointly manages appropriate clinical interventions across the inpatient and outpatient settings.
There is a critical need for guidelines and best clinical practice models from major cardiology
and nephrology professional societies, as well as for research funding in both specialties to
focus on the needs of future therapies for HF in CKD patients. The implementation of crossspecialty educational programs across all levels in cardiology and nephrology will help train
future specialists and nurses who have the ability to diagnose, treat, and prevent HF in CKD
patients in a precise, clinically effective, and cost-favorable manner.Los pacientes con enfermedad renal crónica (ERC) que desarrollan insuficiencia cardíaca (IC)
congestiva crónica presentan cifras inaceptablemente altas de síntomas, hospitalización y
mortalidad. Actualmente, se echan en falta iniciativas institucionales dirigidas a identificar,
prevenir y tratar la IC en los pacientes con ERC de manera multidisciplinar, prevaleciendo
las actuaciones de las especialidades individuales. Los autores de este artículo de revisión
respaldan la necesidad de crear equipos multidisciplinares cardiorrenales, en los que participen nefrólogos y enfermeras renales, que gestionen colaborativamente las intervenciones
clínicas apropiadas en los entornos de pacientes con ERC e IC hospitalizados y ambulatorios.
Es necesario y urgente que se elaboren guías y modelos de práctica clínica sobre la ERC con IC
por parte de las sociedades profesionales de cardiología y nefrología, así como financiación
para la investigación concertada entre ambas especialidades sobre la necesidad de futuros
tratamientos para la IC en pacientes con ERC. La implementación de programas educativos
cardiorrenales a todos los niveles en cardiología y nefrología ayudará a formar a los futuros
especialistas y enfermeras para que tengan la capacidad de diagnosticar, tratar y prevenir
la IC en pacientes con ERC de manera precisa, clínicamente efectiva y económicamente
favorabl
Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain
<p>Abstract</p> <p>Background</p> <p>Rotavirus is the most common cause of gastroenteritis in young children worldwide. The aim of the study was to assess the health outcomes and the economic impact of a universal rotavirus vaccination programme with RotaTeq, the pentavalent rotavirus vaccine, versus no vaccination programme in Spain.</p> <p>Methods</p> <p>A birth cohort was followed up to the age of 5 using a cohort model. Epidemiological parameters were taken from the REVEAL study (a prospective epidemiological study conducted in Spain, 2004-2005) and from the literature. Direct and indirect costs were assessed from the national healthcare payer and societal perspectives by combining health care resource utilisation collected in REVEAL study and unit costs from official sources. RotaTeq per protocol efficacy data was taken from a large worldwide rotavirus clinical trial (70,000 children). Health outcomes included home care cases, General Practioner (GP)/Paediatrician, emergency department visits, hospitalisations and nosocomial infections.</p> <p>Results</p> <p>The model estimates that the introduction of a universal rotavirus vaccination programme with RotaTeq (90% coverage rate) would reduce the rotavirus gastroenteritis (RVGE) burden by 75% in Spain; 53,692 home care cases, 35,187 GP/Paediatrician visits, 34,287 emergency department visits, 10,987 hospitalisations and 2,053 nosocomial infections would be avoided. The introduction of RotaTeq would avoid about 76% of RVGE-related costs from both perspectives: €22 million from the national health system perspective and €38 million from the societal perspective.</p> <p>Conclusions</p> <p>A rotavirus vaccination programme with RotaTeq would reduce significantly the important medical and economic burden of RVGE in Spain.</p
Recommended from our members
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
Breast cancer is a common disease partially caused by genetic risk factors. Germline pathogenic variants in DNA repair genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 are associated with breast cancer risk. FANCM, which encodes for a DNA translocase, has been proposed as a breast cancer predisposition gene, with greater effects for the ER-negative and triple-negative breast cancer (TNBC) subtypes. We tested the three recurrent protein-truncating variants FANCM:p.Arg658*, p.Gln1701*, and p.Arg1931* for association with breast cancer risk in 67,112 cases, 53,766 controls, and 26,662 carriers of pathogenic variants of BRCA1 or BRCA2. These three variants were also studied functionally by measuring survival and chromosome fragility in FANCM -/- patient-derived immortalized fibroblasts treated with diepoxybutane or olaparib. We observed that FANCM:p.Arg658* was associated with increased risk of ER-negative disease and TNBC (OR = 2.44, P = 0.034 and OR = 3.79; P = 0.009, respectively). In a country-restricted analysis, we confirmed the associations detected for FANCM:p.Arg658* and found that also FANCM:p.Arg1931* was associated with ER-negative breast cancer risk (OR = 1.96; P = 0.006). The functional results indicated that all three variants were deleterious affecting cell survival and chromosome stability with FANCM:p.Arg658* causing more severe phenotypes. In conclusion, we confirmed that the two rare FANCM deleterious variants p.Arg658* and p.Arg1931* are risk factors for ER-negative and TNBC subtypes. Overall our data suggest that the effect of truncating variants on breast cancer risk may depend on their position in the gene. Cell sensitivity to olaparib exposure, identifies a possible therapeutic option to treat FANCM-associated tumors
- …